Your browser cannot display this PDF inline.
Download the full opinion (PDF)Background
Magnolia Medical Technologies holds U.S. Patent 10,039,483, directed to a blood sequestration device that reduces microbial contamination in blood samples. The device works by diverting the first small volume of blood drawn — which carries skin bacteria picked up during needle insertion — into a side chamber (the “fluid reservoir”), and channeling subsequent blood directly to the sample collection reservoir, bypassing the contaminated initial draw.
A third party requested ex parte reexamination of claim 1, the patent’s sole independent claim, based on U.S. Patent 6,013,037 (“Brannon”), a 1999 patent disclosing a multi-sample blood collection syringe designed to minimize contamination. The USPTO examiner found that Brannon anticipated claim 1, and the Patent Trial and Appeal Board (PTAB) affirmed in a 2025 decision. Magnolia appealed to the Federal Circuit.
This is not Magnolia’s first Federal Circuit encounter over this patent — an earlier chapter involved a different proceeding concerning the USPTO Director’s IPR institution decision (covered separately on LexSummary). This appeal concerns the ex parte reexamination finding of invalidity.
The Court’s Holding
The Federal Circuit affirmed the PTAB in a per curiam opinion, holding that substantial evidence supports the Board’s finding that Brannon anticipated both disputed limitations of claim 1.
Fluid reservoir limitation: Magnolia argued that Brannon’s “fluid chamber 30” could not meet the claim’s requirement of a reservoir “configured to receive an initial volume of blood withdrawn from the patient” because the chamber is not devoid of blood at the moment of venipuncture (the initial needle stick). The court rejected this argument as a non-sequitur: nothing in claim 1 requires the fluid reservoir limitation to be met at the time of venipuncture. The analysis asks whether the prior art reference discloses each limitation, not whether it does so at a particular moment. Brannon discloses a first sample being contained within fluid chamber 30, which tracks the claim.
Bypass limitation: Magnolia argued that because some initial blood in Brannon ultimately ends up in the collected sample (a “flash” of blood), Brannon does not disclose the subsequent blood bypassing “the initial volume of blood sequestered therein.” The court again disagreed, noting that the claim only requires “an initial volume” to be sequestered — not the entire first draw. Brannon’s disclosure that the fluid chamber is “substantially separated” from subsequent samples was sufficient.
The court also noted that Magnolia’s safety argument — that Brannon’s design would introduce an air embolism risk — was undermined by the PTAB’s observation that Magnolia’s own ‘483 patent describes an embodiment that operates in a materially similar manner.
Key Takeaways
- Anticipation analysis is claim-language-first. Courts assess whether prior art discloses each claim limitation; they do not impose timing or operational conditions that the claims themselves do not recite. Magnolia’s argument that Brannon must satisfy the claim at venipuncture was an extra-textual limitation the Federal Circuit rejected.
- “An” in a patent claim is not “all.” The court’s rejection of Magnolia’s bypass argument turned on the word “an” before “initial volume” — the claim requires sequestration of some initial blood, not every drop that first enters the device.
- Prior art safety concerns can be neutralized by the patent-in-suit. When Magnolia raised safety concerns to distinguish Brannon, the Board and court answered that Magnolia’s own patent embodied the same risk, defeating the distinction.
- Ex parte reexamination remains a potent invalidation tool. A third-party competitor successfully used a 1999 patent to anticipate a claim in a 2018 patent, potentially opening the blood-collection device market.
Why It Matters
Blood contamination during sample collection is a serious clinical problem — false positives from skin bacteria can lead to unnecessary antibiotic treatment and hospital stays. Magnolia’s device was designed to address this by diverting the contaminated first blood draw. With claim 1 now invalid, competitors may have freedom to operate in the blood sequestration space without licensing Magnolia’s patent, which could lower costs and increase availability of contamination-reducing devices.
The case also illustrates the Federal Circuit’s strict approach to anticipation: even a device from the late 1990s can invalidate a later-filed patent if it discloses each claim element, and courts will not read extra-textual timing requirements into claims to save a patent. Patent prosecutors should draft claims with explicit language about temporal conditions if they intend them to be operative only at specific moments in a process.